Form 4: Evolent Health Director Peter J. Grua Receives Significant Restricted Stock Unit Grant

Evolent Health, Inc. Director Peter J. Grua was granted 21,979 restricted stock units of Class A Common Stock, increasing his beneficial ownership in the company.

Summary

• Peter J. Grua, a Director of Evolent Health, Inc. (EVH), acquired 21,979 shares of Class A Common Stock on June 5, 2025.
• These shares represent restricted stock units (RSUs) granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The RSUs were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Mr. Grua directly beneficially owns 40,728 shares of Class A Common Stock.
• Additionally, 41,919 shares are indirectly beneficially owned through the Peter J. Grua 2004 Revocable Trust, where Mr. Grua is the sole trustee with sole voting and dispositive power.
• The total beneficial ownership for Mr. Grua after this transaction is 82,647 shares (40,728 direct + 41,919 indirect).
• The acquired securities will vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, subject to Mr. Grua's continued service.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally a positive signal as it aligns the director's interests with shareholders and incentivizes long-term commitment. It's a routine compensation event, not indicative of operational performance, hence a moderately positive score.

Positives

• The grant of restricted stock units to a director aligns management's interests with shareholders, as vesting is tied to continued service.
• Increases the director's overall beneficial ownership in the company, demonstrating continued commitment.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continued service, meaning the shares could be forfeited if service ceases before the vesting date.

Future Outlook

The document indicates that the granted restricted stock units will vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent on the director's continued service. This implies a continued relationship and incentive for the director over the next year.

Industry Context

This is a standard insider transaction filing (Form 4) for a director receiving equity compensation. It reflects common practices in executive and director compensation across the healthcare technology and services industry, where equity grants are used to align long-term interests.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common practice in publicly traded companies, including those in the healthcare technology sector like Evolent Health. This aligns with typical corporate governance structures that incentivize long-term commitment and performance.
• The vesting schedule (approximately one year, subject to continued service) is also a standard approach for director equity compensation, similar to practices seen in companies like Teladoc Health (TDOC) or Veeva Systems (VEEV) for their non-employee directors.
• The use of a revocable trust for indirect ownership is a common estate planning and asset management strategy for high-net-worth individuals, consistent with practices observed among executives and directors across various industries.

Corporate Governance

Related Party Transactions

• Grant of restricted stock units to Peter J. Grua, a Director of Evolent Health, Inc.
• Indirect beneficial ownership of shares through the Peter J. Grua 2004 Revocable Trust, where Mr. Grua is the sole trustee and has sole voting and dispositive power.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be seen as positive for shareholders as it aligns the director's financial interests with the company's long-term performance and shareholder value creation. It also represents a form of dilution upon vesting, though typically planned for in incentive pools.

Next Steps

• Continued service of Peter J. Grua as a Director of Evolent Health, Inc.
• Vesting of the 21,979 restricted stock units on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting.

Key Dates

Recommendation

Keywords

Evolent Health, EVH, Peter J. Grua, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, beneficial ownership